Literature DB >> 12081625

Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits Abeta1-40 fibrillogenesis.

D J Gordon1, R Tappe, S C Meredith.   

Abstract

Alzheimer's disease, Huntington's disease and prion diseases are part of a growing list of diseases associated with formation of beta-sheet containing fibrils. In a previous publication, we demonstrated that the self-association of the Alzheimer's beta-amyloid (Abeta) peptide is inhibited by peptides homologous to the central core domain of Abeta, but containing N-methyl amino acids at alternate positions. When these inhibitor peptides are arrayed in an extended, beta-strand conformation, the alternating position of N-methyl amino acids gives the peptide two distinct faces, one exhibiting a normal pattern of peptide backbone hydrogen bonds, but the other face having limited hydrogen-bonding capabilities due to the replacement of the amide protons by N-methyl groups. Here, we demonstrate, through two-dimensional NMR and circular dichroic spectroscopy, that a pentapeptide with two N-methyl amino acids, Abeta16-20m or Ac-K(Me)LV(Me)FF-NH2, does indeed have the intended structure of an extended beta-strand. This structure is remarkably stable to changes in solvent conditions and resists denaturation by heating, changes in pH (from 2.5 to 10.5), and addition of denaturants such as urea and guanindine-HCl. We also show that this peptide, despite its hydrophobic composition, is highly water soluble, to concentrations > 30 mm, in contrast to the nonmethylated congener, Abeta16-20 (Ac-KLVFF-NH2). The striking water solubility, in combination with the hydrophobic composition of the peptide, suggested that the peptide might be able to pass spontaneously through cell membranes and model phospholipid bilayers such as unilamellar vesicles. Thus, we also demonstrate that this peptide is indeed able to pass spontaneously through both synthetic phospholipid bilayer vesicles and cell membranes. Characterization of the biophysical properties of the Abeta16-20m peptide may facilitate the application of this strategy to other systems as diverse as the HIV protease and chemokines, in which there is dimerization through beta-strand domains.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12081625     DOI: 10.1034/j.1399-3011.2002.11002.x

Source DB:  PubMed          Journal:  J Pept Res        ISSN: 1397-002X


  38 in total

1.  Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42.

Authors:  Takeshi Sato; Pascal Kienlen-Campard; Mahiuddin Ahmed; Wei Liu; Huilin Li; James I Elliott; Saburo Aimoto; Stefan N Constantinescu; Jean-Noel Octave; Steven O Smith
Journal:  Biochemistry       Date:  2006-05-02       Impact factor: 3.162

2.  Structure-based design of conformation- and sequence-specific antibodies against amyloid β.

Authors:  Joseph M Perchiacca; Ali Reza A Ladiwala; Moumita Bhattacharya; Peter M Tessier
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-14       Impact factor: 11.205

3.  Probing the efficacy of peptide-based inhibitors against acid- and zinc-promoted oligomerization of amyloid-β peptide via single-oligomer spectroscopy.

Authors:  Lyndsey R Powell; Kyle D Dukes; Robin K Lammi
Journal:  Biophys Chem       Date:  2011-09-08       Impact factor: 2.352

4.  Chaperone-like N-methyl peptide inhibitors of polyglutamine aggregation.

Authors:  Jennifer D Lanning; Andrew J Hawk; Johnmark Derryberry; Stephen C Meredith
Journal:  Biochemistry       Date:  2010-08-24       Impact factor: 3.162

5.  A two-step strategy for structure-activity relationship studies of N-methylated aβ42 C-terminal fragments as aβ42 toxicity inhibitors.

Authors:  Huiyuan Li; Reeve Zemel; Dahabada H J Lopes; Bernhard H Monien; Gal Bitan
Journal:  ChemMedChem       Date:  2012-02-03       Impact factor: 3.466

6.  Effects of peptides derived from terminal modifications of the aβ central hydrophobic core on aβ fibrillization.

Authors:  Cyrus K Bett; Wilson K Serem; Krystal R Fontenot; Robert P Hammer; Jayne C Garno
Journal:  ACS Chem Neurosci       Date:  2010-08-26       Impact factor: 4.418

7.  Structure-activity relationships in peptide modulators of β-amyloid protein aggregation: variation in α,α-disubstitution results in altered aggregate size and morphology.

Authors:  Cyrus K Bett; Johnpeter N Ngunjiri; Wilson K Serem; Krystal R Fontenot; Robert P Hammer; Robin L McCarley; Jayne C Garno
Journal:  ACS Chem Neurosci       Date:  2010-07-08       Impact factor: 4.418

8.  Benchmarking implicit solvent folding simulations of the amyloid beta(10-35) fragment.

Authors:  Andrew Kent; Abhishek K Jha; James E Fitzgerald; Karl F Freed
Journal:  J Phys Chem B       Date:  2008-03-19       Impact factor: 2.991

9.  Kinetics and mechanical stability of the fibril state control fibril formation time of polypeptide chains: A computational study.

Authors:  Maksim Kouza; Nguyen Truong Co; Mai Suan Li; Sebastian Kmiecik; Andrzej Kolinski; Andrzej Kloczkowski; Irina Alexandra Buhimschi
Journal:  J Chem Phys       Date:  2018-06-07       Impact factor: 3.488

10.  Oligomerization of FVFLM peptides and their ability to inhibit beta amyloid peptides aggregation: consideration as a possible model.

Authors:  M Kouza; A Banerji; A Kolinski; I A Buhimschi; A Kloczkowski
Journal:  Phys Chem Chem Phys       Date:  2017-01-25       Impact factor: 3.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.